Skip to content
HowShorted

Clovis Oncology, Inc. short interest in 2022

In 2022, Clovis Oncology, Inc.'s disclosed short interest ran from 20.54% of shares outstanding on 14 Jan 2022 to 16.75% on 15 Dec 2022, a change of -3.79 percentage points. The year's high was 29.58% on 30 Jun 2022 and its low 15.03% on 31 Mar 2022, averaging 21.33% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.09 days on 31 Oct 2022. Full history: Clovis Oncology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Clovis Oncology, Inc. in 2022

2022 in figures

Start of year
20.54% (14 Jan 2022)
End of year
16.75% (15 Dec 2022)
Change
-3.79 pp
High
29.58% (30 Jun 2022)
Low
15.03% (31 Mar 2022)
Average
21.33%
Highest days to cover
20.09 (31 Oct 2022)
SEC filings marked
8

Every report in 2022

Clovis Oncology, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202220.54%6.76results (8-K)
31 Jan 202221.51%5.27
15 Feb 202221.24%6.04
28 Feb 202219.64%6.39results (8-K), 10-K filed
15 Mar 202218.79%6.43
31 Mar 202215.03%1.00
14 Apr 202220.28%1.23
29 Apr 202219.26%5.99
13 May 202225.21%3.43results (8-K), 10-Q filed
31 May 202227.42%10.07
15 Jun 202228.67%3.46
30 Jun 202229.58%1.73
15 Jul 202219.86%1.00
29 Jul 202219.43%6.21
15 Aug 202220.53%7.0510-Q filed, results (8-K)
31 Aug 202220.07%11.05
15 Sep 202222.95%5.41
30 Sep 202221.81%13.66
14 Oct 202221.79%17.26
31 Oct 202221.30%20.09
15 Nov 202219.33%2.7310-Q filed
30 Nov 202219.65%14.40
15 Dec 202216.75%2.44

See also: Clovis Oncology, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.